Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX038 in Locally Advanced or Metastatic Triple-negative Breast Cancer
NCT06162351Phase 2Terminated
- Sponsor
- Institut Curie
- Start
- Apr 2024
- Primary completion
- May 2025
- Modality
- Polymer-based Nanoparticles, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PLX038 in triple-negative breast cancer (TNBC), sponsored by Institut Curie. Primary endpoint: Best tumor response at 24 weeks. Started Apr 2024; status: terminated.
02
Drugs
PLX038
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06162351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06162351.